Valeant Cuts 2016 Revenue Forecast

Valeant Pharmaceuticals International Inc cut its revenue forecast for the year by about 12 percent, or $1.5 billion, citing slower growth in its U.S. dermatology, gastrointestinal and women's health businesses.